SCHEMBL29292080

SCHEMBL29292080

CSNCCCOc1cccc(-c2cccc(C)c2)c1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 4/20 0.54
▸ DRD4 P21917 4/20 0.54
▸ DRD3 P35462 3/20 0.52
▸ F2 P00734 1/20 0.47
▸ POLB P06746 1/20 0.45
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ MAPK1 P28482 3/20 0.41
▸ HPGD P15428 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24061152 0.78 L3MBTL1 (0.62) DRD2DRD4DRD3POLBL3MBTL1
SCHEMBL8265682 0.77 ALDH1A1 (0.52) DRD2DRD4DRD3F2POLB
SCHEMBL18655581 0.76 TSHR (0.59) DRD2DRD4SMN1; SMN2CYP1A2CYP2D6
SCHEMBL12958255 0.76 DRD2 (0.48) DRD2DRD4DRD3SMN1; SMN2KDM4E
SCHEMBL18655582 0.76 TSHR (0.59) DRD2DRD4SMN1; SMN2CYP1A2CYP2D6
SCHEMBL8264819 0.75 MAOB (0.58) DRD2DRD4KMT2ASMN1; SMN2KDM4E
SCHEMBL14308606 0.73 DRD2 (0.69) DRD2DRD4DRD3F2POLB
SCHEMBL31663663 0.73 DRD2 (0.84) DRD2DRD4DRD3F2POLB
SCHEMBL23067879 0.73 DRD2 (0.84) DRD2DRD4DRD3F2POLB
SCHEMBL12225772 0.73 RXRA (0.57) SMN1; SMN2KDM4EL3MBTL1MAPK1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4157844-B1 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER CENTRE NAT RECH SCIENT (FR) 2024-07-10 — — EP disclosed
Send feedback